Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXPEDITION OLE long-term safety study of brazikumab in ulcerative colitis
2021-001644-10Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of brazikumab in autoimmune colitis, sponsored by AstraZeneca. Started Aug 2021; status: completed.
02
Drugs
brazikumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2021-001644-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001644-10.